A Neglected Case of Multifocal Liposarcoma Presented in Five Different Sites in a Syrian Woman: A case report

ConclusionMedicine cannot provide much care for these advanced cases of multicentric liposarcoma so far. Therefore, more research should be conducted to improve the ability to manage these entities and to identify potential novel therapies.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research

Related Links:

mes L. Chen Soft tissue sarcomas (STS) are diverse tumors with heterogenous alterations. Platforms to detect circulating tumor DNA (ctDNA) have rapidly increased in popularity as they may avoid invasive biopsy morbidity. However, ctDNA profiling concordance with standard solid tumor comprehensive genomic profiling (CGP) is poorly characterized. Here, we report the outcomes of a single-institution experience comparing mutational results from commercial ctDNA and solid tumor CGP in advanced STS subjects. We identified STS subjects who had undergone solid tumor based CGP in four distinct cohorts: Dedifferentiated liposarc...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionsThese interim results suggest that ERI may be an option for patients with various types of STS, including non-L-type sarcomas.Legal entity responsible for the studyEisai Co., Ltd.FundingEisai Co., Ltd.DisclosureS. Takahashi: Advisory / Consultancy: Eisai Co., Ltd. Y. Megumi: Full / Part-time employment: Eisai Co., Ltd. Y. Sakata: Full / Part-time employment: Eisai Co., Ltd. H. Ikezawa: Full / Part-time employment: Eisai Co., Ltd. T. Matsuoka: Full / Part-time employment: Eisai Co., Ltd. A. Kawai: Advisory / Consultancy: Eisai Co., Ltd.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsT concurrent with RT showed a relevant activity in progressing metastatic setting in a wide range of STS types, giving options for tumor shrinkage beyond the first-line of advanced STS. The RECIST ORR of 57.7% and 6-m PFSR of 75% confirm the synergy of T+RT.Clinical trial identificationNCT02275286.Legal entity responsible for the studyGEIS (Spanish Group for Research on Sarcoma).FundingGEIS, ISG (Italian Sarcoma Group), FSG (French Sarcoma Group); PharmaMar.DisclosureJ. Martin Broto: Research grant / Funding (institution): EISAI; Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundSoft-tissue sarcomas (STS) are life-threatening diseases, for which more efficient therapeutic options are necessary. Trabectedin (T) is an anti-tumor drug approved for the treatment of advanced STS. Synergistic drug combinations could improve T results in STS patients. Rapamycin (R) is an mTOR pathway inhibitor. Synergy with T has been described in ovary clear cell carcinoma. Of note, R suppresses DNA double-strand breaks repair, thus generating the perfect set-up for T activity. Altogether, we hypothesize that T+R combination (T+R) is synergistic in STS, and that mTOR inhibition enhances T activity.Meth...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionIncidence rates of STS and BS have been stable since 2001. The longer RS in STS can be attributed to advances in sarcoma patient management.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Conclusion: Trabectedin 1.2 mg/m2, as the approved dose in Japan, showed similar efficacy to the dose of 1.5 mg/m2 used in Western countries. Trabectedin could be an option for advanced STS in Japan, regardless of histological subtype.
Source: In Vivo - Category: Research Authors: Tags: Clinical Studies Source Type: research
Authors: Chen M, Xu ES, Leisenring NH, Cardona DM, Luo L, Ma Y, Ventura A, Kirsch DG Abstract Myxoid liposarcoma is a malignant soft tissue sarcoma characterized by a pathognomonic t(12;16)(q13;p11) translocation that produces a fusion oncoprotein, FUS-CHOP. This cancer is remarkably sensitive to radiotherapy and exhibits a unique pattern of extrapulmonary metastasis. Here, we report the generation and characterization of a spatially and temporally restricted mouse model of sarcoma driven by FUS-CHOP. Using different Cre drivers in the adipocyte lineage, we initiated in vivo tumorigenesis by expressing FUS-CHOP in ...
Source: Sarcoma - Category: Cancer & Oncology Tags: Sarcoma Source Type: research
Conclusion.Although overall survival of patients with STS with synchronous metastases in this nationwide and “real‐life” population has improved over the years, the improvement was not statistically significant, despite new treatment options.Implications for Practice.Treatment of patients with metastatic soft tissue sarcoma (STS) has changed in the past years, with new drugs such as trabectedin (2007) and pazopanib (2012) becoming available. By using data from the nationwide Netherlands Cancer Registry, the impact of these changes in treatment policies on survival is analyzed in a “real‐life” po...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Sarcomas, European Perspectives Source Type: research
Conclusions: The strongest predictors of disease-free and overall survival are tumor-specific characteristics, while surgical factors are less impactful. Nonsurgical therapies are not associated with improved outcomes despite persistent interest and utilization. Complete macroscopic resection (R0/R1) remains a persistent potentially modifiable risk factor associated with improved overall survival in patients with retroperitoneal sarcomas. PMID: 31281208 [PubMed]
Source: Sarcoma - Category: Cancer & Oncology Tags: Sarcoma Source Type: research
Authors: Verboom MC, Gelderblom H, Kerst JM, Steeghs N, Reyners AKL, Sleijfer S, van der Graaf WTA, van den Hout WB Abstract Trabectedin and ifosfamide are among the few cytostatic agents active in advanced soft tissue sarcomas (STSs). Trabectedin is most potent against so-called L-sarcomas (leiomyosarcoma and liposarcoma). The survival gain and cost-effectiveness of these agents in a second-line setting were analysed in the setting of advanced STS after failure of anthracyclines. A prospective observational trial had previously been performed to assess the use of trabectedin in a Dutch real-world setting. Data on ...
Source: Sarcoma - Category: Cancer & Oncology Tags: Sarcoma Source Type: research
More News: Genetics | International Medicine & Public Health | Liposarcoma | Sarcomas | Soft Tissue Sarcoma | Surgery | Syria Health | WHO